ProPhase Labs/PRPH

$5.26

-3.3%
-
1D1W1MYTD1YMAX

About ProPhase Labs

ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.

Ticker

PRPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Ted Karkus

Employees

113

Headquarters

New york, United States

ProPhase Labs Metrics

BasicAdvanced
$113.14M
Market cap
-
P/E ratio
-$0.95
EPS
-0.25
Beta
-
Dividend rate
$113.14M
-0.25251
$9.94
$4.05
30.66K
2.281
2.097
14.207
17.933
-18.06%
-18.69%
-29.7%
-23.53%
2.549
2.291
3.556
-63.81%
-197.08%
45.15%

What the Analysts think about ProPhase Labs

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
280.23% upside
High $20.00
Low $20.00
$5.26
Current price
$20.00
Average price target

ProPhase Labs Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-255.88% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.4M
-59.04%
Net income
$-8.7M
70.59%
Profit margin
-255.88%
316.47%

ProPhase Labs Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 96.15%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.03
-$0.20
-$0.30
-$0.51
-
Expected
-$0.09
-$0.14
-$0.20
-$0.26
-$0.41
Surprise
-133.33%
42.86%
53.85%
96.15%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ProPhase Labs stock?

ProPhase Labs (PRPH) has a market cap of $113.14M as of April 20, 2024.

What is the P/E ratio for ProPhase Labs stock?

The price to earnings (P/E) ratio for ProPhase Labs (PRPH) stock is 0 as of April 20, 2024.

Does ProPhase Labs stock pay dividends?

No, ProPhase Labs (PRPH) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next ProPhase Labs dividend payment date?

ProPhase Labs (PRPH) stock does not pay dividends to its shareholders.

What is the beta indicator for ProPhase Labs?

ProPhase Labs (PRPH) has a beta rating of -0.25. This means that it has an inverse relation to market volatility.

What is the ProPhase Labs stock price target?

The target price for ProPhase Labs (PRPH) stock is $20, which is 280.23% above the current price of $5.26. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ProPhase Labs stock

Buy or sell ProPhase Labs stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing